Avenue, Room 604, Bethesda, MD 20892–9121, or call (301) 402–5666 (this is not a toll-free number), or e-mail your request, including your address, to <mh18k@nih.gov>, or access the Scholarship Office on the Internet at <http://helix.nih.gov:8001/oe/catalog/loanrepay.html>.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received on or before November 25, 1996.

Dated: October 16, 1996.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 96–27326 Filed 10–23–96; 8:45 am]

BILLING CODE 4140–01–M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

The inventions referenced below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and a copy of the patent application and issued patents may be obtained by contacting Elaine Gese at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804 (telephone 301/496–7056 ext 282; fax 301/402–0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

Plant Protein Useful for Treating Tumors and HIV Infection

Sylvia Lee-Huang, et al.

U.S. Patent 5,484,889 issued January 16, 1996

MAP 30, a 30 kDa basic protein, which may be purified from *Momordica charantia* fruit or seed extracts or produced by recombinant DNA technology, is useful in treating HIV infection and cancer. *M. charantia*, commonly known as bitter melon, is a medicinal plant whose extracts have been used for centuries in China and Southeast Asia as antiinfection and antitumor agents. MAP 30 is capable of inhibiting HIV–1 infection in T lymphocytes and monocytes as well as replication of HIV–1 in infected cells, yet is not toxic to normal uninfected cells. The biological properties of MAP 30 include: (1) N-glycosidase activity on 28S ribosomal RNA; (2) topological activity on plasmid and viral DNAs including HIV–1 LTRs; and (3) dose-dependent inhibition of HIV–1 integrase. Three recent publications describing MAP 30 are: Lee-Huang, et al., ''Proteolytic fragments of anti-HIV proteins MAP30 and GAP31 are biologically active,'' XI International Conference on AIDS (abstract); Lee-Huang, S., et al., ''Inhibition of the integrase of human immunodeficiency virus (HIV) by anti-HIV plant proteins MAP30 and GAP31,'' *Proc. Natl. Acad. Sci.* 92: 8818–8822 (1995); and Lee-Huang, S., et al., ''Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon,'' *Gene* 161: 151–156 (1995). The cloning and expression of the gene encoding biologically active recombinant MAP30 provides an abundant source of homogeneous material for clinical investigations. The patent discloses purified natural and recombinant protein, processes for purifying the protein, DNA sequences encoding the protein, and recombinant methods for expressing the protein. Foreign patent rights are available in Australia, Canada, Europe, and Japan. (portfolios: Infectious Diseases—Therapeutics, anti-virals, AIDS; Cancer—Therapeutics, other)

Anti-HIV Proteins GAP 31, DAP 30 and DAP 32 and Therapeutic Uses Thereof

Sylvia Lee-Huang, et al.

U.S. Patent 5,317,009 issued May 31, 1995

GAP 31, a 31 kDa protein, and DAP 30 and 32, 30 and 32 kDa proteins, respectively, which may be purified from extracts of *Gelonium multiflorum* (a medicinal plant) and *Dianthus caryophyllus* (carnation), respectively, or produced by recombinant DNA technology, are useful in treating HIV infection. GAP 31 also exhibits anti-tumor activity. These proteins belong to the family of single-chain ribosome-inactivating proteins (SCRIPS), which inactive ribosomes in cell-free systems but are relatively nontoxic to intact cells. The biological properties of GAP 31 include: (1) N-glycosidase activity on 28S ribosomal RNA; (2) topological activity on plasmid and viral DNAs including HIV–1 LTRs; and (3) dose-dependent inhibition of HIV–1 integrase. Two recent publications concerning GAP 31 are: Lee-Huang, et al., ''Proteolytic fragments of anti-HIV proteins MAP30 and GAP31 are biologically active,'' XI International Conference on AIDS (abstract) and Lee-Huang, S., et al., ''Inhibition of the integrase of human immunodeficiency virus (HIV) by anti-HIV plant proteins MAP30 and GAP31,'' *Proc. Natl. Acad. Sci.* 92: 8818–8822 (1995). The cloning and expression of the genes encoding biologically active recombinant GAP31, and DAP 30 and 32 provides an abundant source of homogeneous material for clinical investigations. The patent discloses purified natural and recombinant proteins, processes for purifying the proteins, DNA sequences encoding the proteins, and recombinant methods for expressing the proteins. Foreign patent rights are available in Australia, Canada, Europe, and Japan. (portfolio: Infectious Diseases—Therapeutics, anti-virals, AIDS)

An Anti-HIV Protein, TAP 29, From Trichosanthes, DNA Coding Therefor and Therapeutic Uses Thereof

Sylvia Lee-Huang, et al.

U.S. Patent Application 08/275,327 filed October 26, 1992

TAP 29, a 29 kDA protein which may be purified from the root tuber of the plant *Trichosanthes kirilowii* or produced by recombinant DNA technology, is useful in treating HIV infection and also exhibits anti-tumor activity. TAP 29 is a single-chain ribosome-inactivating protein (SCRIP) which inactivates ribosomes in cell-free systems but is relatively nontoxic to intact cells. TAP 29 has anti-HIV activity equivalent to trichosanthin but has a lower in vitro toxicity with a therapeutic index of approximately 5000. The cloning and expression of the gene encoding biologically active recombinant TAP 29 provides an abundant source of homogeneous material for clinical investigations. TAP 29 is further described in ''TAP 29: An anti-human immunodeficiency virus protein from *Trichosanthes kirilowii* that is nontoxic to intact cells,'' *Proc. Natl. Acad. Sci.* 88: 6570 (1991) and ''Plant proteins with antiviral activity against human immunodeficiency virus,'' in Natural Products as Antiviral Agents (C.K. Chu, ed., 1992). The natural protein, the DNA coding therefore, an antibody specific therefore, a method for purifying the natural protein, and the recombinant protein are provided. Foreign patent rights are available in Australia, Canada, Europe, and Japan. (portfolio: Infectious Diseases—Therapeutics, anti-virals, AIDS)

Dated: October 11, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96–27331 Filed 10–23–96; 8:45 am]

BILLING CODE 4140–01–M

Notice of Meeting of the NIH Director's Advisory Panel on Clinical Research

Notice is hereby given that the NIH Director's Advisory Panel on Clinical Research, a group reporting to the Advisory Committee to the Director (ACD), National Institutes of Health (NIH), will meet in public session at the William H. Natcher Building (Building 45) Conference Center, Conference Room E1/E2, National Institutes of Health, Bethesda, Maryland 20892, on November 5, 1996 from 8:30 a.m. until approximately 12:30 p.m.

The goal of the Panel is to review the status of clinical research in the United States, and to make recommendations to the ACD about how to ensure its effective continuance. Topics to be considered at this meeting are subcommittee reports and a discussion of the proposed report to be presented by the Panel Chair to the ACD in December 1996.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other special accommodations, should contact the person named below in advance of the meeting.

Attendance may be limited to seat availability. If you plan to attend the meeting as an observer or if you wish additional information, please contact Mrs. Janet Smith, National Institutes of Health, Building 10, Room 1C–116, 10 Center Drive, MSC 1154, Bethesda, Maryland 20892–1154, telephone (301) 402–3444, fax (301) 402–3443, by October 28, 1996.

Dated: October 16, 1996.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 96–27329 Filed 10–23–96; 8:45 am]

BILLING CODE 4140–01–M

National Center for Research Resources; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Center for Research Resources Special Emphasis Panel (SEP) meetings:

Name of SEP: General Clinical Research Centers.

Date: November 6–8, 1996.

Time: 3:00 p.m.—until adjournment.

Place: The New O'Tani, 120 S. Los Angeles Street, Los Angeles, California 90012, (213) 629–1200.

Contact Person: Dr. John Lymangrover, Scientific Review Administrators, 6705 Rockledge Drive, MSC 7965, Room 6018, Bethesda, MD 20892–7965, (301) 435–0820.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Name of SEP: General Clinical Research Centers.

Date: January 21–22, 1997.

Time: 7:45 a.m.—until adjournment.

Place: Doubletree Hotel Albuquerque, 201 Marquette N.W., Albuquerque, New Mexico 87102, (505) 247–3344.

Contact Person: Dr. Charles Hollingsworth, Scientific Review Administrators, 6705 Rockledge Drive, MSC 7965, Room 6018, Bethesda, MD 20892–7965, (301) 435–0820.

Purpose/Agenda: To evaluate and review grant applications.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal property.

(Catalog of Federal Domestic Assistance Program No. 93.333, Clinical Research, National Institutes of Health, HHS)

Dated: October 17, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96–27320 Filed 10–23–96; 8:45 am]

BILLING CODE 4140–01–M

National Center for Human Genome Research; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

Agenda/Purpose: To review and evaluate grant applicants and/or contract proposals.

Name of Committee: National Center for Human Genome Research Initial Review Group, Genome Research Review Subcommittee.

Date: November 4, 1996.

Time: 8:30 am.

Place: NIH, Natcher (Building 45), Room F1, 9000 Rockville Pike, Bethesda, Maryland.

Contact Person: Rudy Pozzatti, Ph.D., Office of Scientific Review, National Center for Human Genome Research, National Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 20892, (301) 402–0838.

Name of Committee: National Center for Human Genome Research Special Emphasis Panel 01.

Date: November 4, 1996.

Time: 11:00 am.

Place: NIH, Natcher (Building 45), Room F1, 9000 Rockville Pike, Bethesda, Maryland.

Contact Person: Rudy Pozzatti, Ph.D., Office of Scientific Review, National Center for Human Genome Research, National Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 20892, (301) 402–0838.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The applications and/or contract proposals, and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program No. 93.172, Human Genome Research)

Dated: October 16, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96–27330 Filed 10–23–96; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Initial Review Group (IRG) meeting:

Name of IRG: Heart, Lung, and Blood Program Project Review Committee.

Date: December 5–6, 1996.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland 20815.

Contact Person: Dr. Jeffrey H. Hurst, Scientific Review Administrator, NHLBI/Review Branch, 6701 Rockledge Drive, Rm. 7208, Bethesda, Maryland 20892, (301) 435–0303.

Purpose/Agenda: To review and evaluate program project grant applications.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular